Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Feb 02, 2021 10:14pm
94 Views
Post# 32455053

RE:RE:RE:Clinical and economic impact of ibalizumab

RE:RE:RE:Clinical and economic impact of ibalizumabThanks Scarlet - I guess I've missed something, but where do you get those granular monthly unit volumes? Is that the Bloomberg data, IVIQ or. from an analyst or Taimed? I've stopped analyzing the monthly's but have to admit they did a pretty good job through this massive healthcare crisis. A little bumpy still, but commendable under the circumstances. I guess it shows one benefit from being a life saving drug. 


scarlet1967 wrote: Correct myself the average is the average regardless of big or small orders, Whish is about 58000 units per month for the last 13 months.


scarlet1967 wrote: It was posted earlier but thank you for being a proactive investor looking for news.
As per Trogarzo units orders in the last 13 months THTX placed a total orders summing up to 763801 units with an average monthly units of 58000.
As per January 2021 the last order was about 42000 units and in December 2020 they ordered little over 40000 which is below the average but in the 2020 THTX due to the pandemic placed a couple of big orders for instance in March the biggest order was 119016 units followed by couple of months of well over 65000 units and in July the placed their second biggest order in the last 13 months well over 95000 units I guess they wanted to fill the inventory in case of covid19 related manufacturing issues would cause supply problems.
So we are looking at above 60000 units per month taking those big orders in the equation.
Mesning despite filling the inventory early in the process they are still placing orders..,,,


Saurus100 wrote: Here is a report on Ibalizumab...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066538/#!po=0.724638

 

 




<< Previous
Bullboard Posts
Next >>